Compare QDEL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | MRVI |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 989.5M | 1.1B |
| IPO Year | 2022 | 2020 |
| Metric | QDEL | MRVI |
|---|---|---|
| Price | $13.33 | $7.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $14.67 | $8.50 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $185,743,000.00 |
| Revenue This Year | N/A | $14.01 |
| Revenue Next Year | $1.85 | $6.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.92 | $2.55 |
| 52 Week High | $35.58 | $9.42 |
| Indicator | QDEL | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 47.36 |
| Support Level | $13.04 | $6.41 |
| Resistance Level | $17.86 | $7.60 |
| Average True Range (ATR) | 1.09 | 0.54 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 67.80 | 28.51 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.